Related Experiment Videos
[In-stent restenosis: which indications for drug-eluting stent?]
H Eltchaninoff1, C Tron, A Cribier
1Service de cardiologie, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen, France. helene.eltchaninoff@chu-rouen.fr
Annales De Cardiologie Et D'Angeiologie
|August 27, 2003
Abstract:
In-stent restenosis remains a limitation of stent implantation. Currently, at the exception of brachytherapy, any percutaneous technique is associated with a high recurrent restenosis rate (> 50%) in diffuse in-stent restenosis. Although based on a small number of patients, eluting stents (sirolimus, paclitaxel) appear promising for the treatment of instent restenosis.